Freenome Stock
Multiomics Platform for Early Disease Screening
Sign up today and learn more about Freenome Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Freenome Stock
Headquartered in South San Francisco, Freenome is a health technology company developing accurate, accessible and non-invasive disease screening products for proactively treating cancer and other diseases at their most manageable stages. Freenome aims to reinvent disease management through systematized early detection and intervention. Since launching in 2014, the company has raised more than $70 million from leading technology and healthcare investors.
Investors
Andreessen Horowitz
Lyft, Robinhood, Databricks, Airbnb, Instacart, Stripe, Magic Leap, Rappi, CoinSwitch Kuber, Devoted Health
T. Rowe Price
One97, Flipkart, WeWork, Cruise, Airbnb, Rivian, Magic Leap, Nuro, Caris Life Sciences, Vroom
Founders Fund
Lyft, Spotify, Airbnb, Stripe, Anduril Industries, Flexport, Palantir Technologies, Wish, Compass, Zenefits
Funding History
October 2015 | $800K |
---|---|
June 2016 | $5.6M |
August 2017 | $72.0M |
June 2019 | $165M |
July 2020 | $270M |
Management
Chief Executive Officer
Mike Nolan
Chief Financial Officer
William Quirk
Press
fiercebiotech - Apr, 6 2024
Roche leads Freenome's $254M funding for cancer blood testsfinance - Apr, 6 2024
Freenome raises $254M to study cancer screening testsreuters - Apr, 6 2024
Cancer test firm Freenome raises $254 mln in fresh fundingprnewswire - Apr, 6 2024
Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detectionthefly - Apr, 3 2024
Canaccord positive on Exact, Guardant after Freenome data